Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Gut Liver. 2021 Jul 15;15(4):606-615. doi: 10.5009/gnl20267.
BACKGROUND/AIMS: Recent data indicate the presence of liver enzyme abnormalities in patients with coronavirus disease 2019 (COVID-19). We aimed to evaluate the clinical features and treatment outcomes of COVID-19 patients with abnormal liver enzymes.
We performed a retrospective, multicenter study of 874 COVID-19 patients admitted to five tertiary hospitals from February 20 to April 14, 2020. Data on clinical features, laboratory parameters, medications, and treatment outcomes were collected until April 30, 2020, and compared between patients with normal and abnormal aminotransferases.
Abnormal aminotransferase levels were observed in 362 patients (41.1%), of which 94 out of 130 (72.3%) and 268 out of 744 (36.0%) belonged to the severe and non-severe COVID- 19 categories, respectively. The odds ratios (95% confidence interval) for male patients, patients with a higher body mass index, patients with severe COVID-19 status, and patients with lower platelet counts were 1.500 (1.029 to 2.184, p=0.035), 1.097 (1.012 to 1.189, p=0.024), 2.377 (1.458 to 3.875, p=0.001), and 0.995 (0.993 to 0.998, p>0.001), respectively, indicating an independent association of these variables with elevated aminotransferase levels. Lopinavir/ ritonavir and antibiotic use increased the odds ratio of abnormal aminotransferase levels after admission (1.832 and 2.646, respectively, both p<0.05). The median time to release from quarantine was longer (22 days vs 26 days, p=0.001) and the mortality rate was higher (13.0% vs 2.9%, p<0.001) in patients with abnormal aminotransferase levels.
Abnormal aminotransferase levels are common in COVID-19 patients and are associated with poor clinical outcomes. Multivariate analysis of patients with normal aminotransferase levels on admission showed that the use of lopinavir/ritonavir and antibiotics was associated with abnormal aminotransferase levels; thus, careful monitoring is needed.
背景/目的:最近的数据表明,2019 年冠状病毒病(COVID-19)患者存在肝酶异常。我们旨在评估肝功能异常的 COVID-19 患者的临床特征和治疗结果。
我们对 2020 年 2 月 20 日至 4 月 14 日从五所三级医院收治的 874 例 COVID-19 患者进行了回顾性、多中心研究。收集了临床特征、实验室参数、药物和治疗结果的数据,直至 2020 年 4 月 30 日,并比较了肝功能正常和异常患者之间的数据。
362 例(41.1%)患者的肝转氨酶水平异常,其中 130 例中的 94 例(72.3%)和 744 例中的 268 例(36.0%)分别属于重症和非重症 COVID-19 类别。男性患者、体重指数较高的患者、重症 COVID-19 状态患者和血小板计数较低的患者的比值比(95%置信区间)分别为 1.500(1.029 至 2.184,p=0.035)、1.097(1.012 至 1.189,p=0.024)、2.377(1.458 至 3.875,p=0.001)和 0.995(0.993 至 0.998,p>0.001),表明这些变量与肝转氨酶升高独立相关。洛匹那韦/利托那韦和抗生素的使用增加了入院后肝转氨酶异常的比值比(分别为 1.832 和 2.646,均 p<0.05)。肝功能异常患者的隔离解除中位时间较长(22 天比 26 天,p=0.001),死亡率较高(13.0%比 2.9%,p<0.001)。
肝功能异常是 COVID-19 患者的常见现象,并与不良临床结局相关。对入院时肝功能正常的患者进行多变量分析显示,洛匹那韦/利托那韦和抗生素的使用与肝转氨酶异常有关;因此,需要密切监测。